JPH04290822A - Allergy preventing medicine and food - Google Patents
Allergy preventing medicine and foodInfo
- Publication number
- JPH04290822A JPH04290822A JP3075882A JP7588291A JPH04290822A JP H04290822 A JPH04290822 A JP H04290822A JP 3075882 A JP3075882 A JP 3075882A JP 7588291 A JP7588291 A JP 7588291A JP H04290822 A JPH04290822 A JP H04290822A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- linolenic acid
- sesamin
- allergy
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 18
- 235000013305 food Nutrition 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 206010020751 Hypersensitivity Diseases 0.000 title claims description 19
- 230000007815 allergy Effects 0.000 title claims description 13
- 239000003921 oil Substances 0.000 claims abstract description 37
- 235000019198 oils Nutrition 0.000 claims abstract description 37
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 32
- 235000019197 fats Nutrition 0.000 claims abstract description 19
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 16
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 16
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 16
- 239000008159 sesame oil Substances 0.000 claims abstract description 16
- 235000004347 Perilla Nutrition 0.000 claims abstract description 14
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 12
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 244000124853 Perilla frutescens Species 0.000 claims abstract 4
- 244000269722 Thea sinensis Species 0.000 claims description 7
- 229940069445 licorice extract Drugs 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 6
- 229930013686 lignan Natural products 0.000 claims description 3
- -1 lignan compound Chemical class 0.000 claims description 3
- 235000009408 lignans Nutrition 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 19
- 239000003925 fat Substances 0.000 abstract description 16
- 238000002156 mixing Methods 0.000 abstract description 6
- 230000000172 allergic effect Effects 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 4
- 241000207961 Sesamum Species 0.000 abstract 1
- 235000003434 Sesamum indicum Nutrition 0.000 abstract 1
- 239000005445 natural material Substances 0.000 abstract 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 150000002617 leukotrienes Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 description 5
- 239000006014 omega-3 oil Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 3
- 229940033080 omega-6 fatty acid Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229940123980 Desaturase inhibitor Drugs 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は、アレルギー予防薬およ
び食品に関するものである。TECHNICAL FIELD The present invention relates to allergy preventive drugs and foods.
【0002】0002
【従来の技術】現在、アレルギー患者の急増は生活環境
の変化にともなうアレルゲン(カビ、ダニ、花粉等)に
対する生体反応の上昇が一因といわれている。しかし、
食生活の欧米化にともない、リノール酸の過剰摂取から
、必須脂肪酸のバランスが崩れたことが主な要因である
ことが近年指摘されてきている。BACKGROUND OF THE INVENTION At present, the rapid increase in the number of allergic patients is said to be partly due to an increase in biological reactions to allergens (mold, mites, pollen, etc.) due to changes in the living environment. but,
In recent years, it has been pointed out that the main cause of this is an imbalance of essential fatty acids due to excessive intake of linoleic acid due to the Westernization of dietary habits.
【0003】奥山(名古屋名市立大学 薬学部)らは
、α−リノレン酸含有油脂を摂取させることにより、生
体中のアレルギー反応の原因物質であるロイコトリエン
の産生を抑制することができると報告している(フ゜ロ
スタク゛ランシ゛ン.,36,3(1988))。[0003] Okuyama et al. (Faculty of Pharmaceutical Sciences, Nagoya City University) have reported that the production of leukotrienes, which are the causative agents of allergic reactions in living organisms, can be suppressed by ingesting fats and oils containing α-linolenic acid. (Front Strategy, 36, 3 (1988)).
【0004】また、他のω3系脂肪酸であるエイコサペ
ンタエン酸、ドコサヘキサエン酸にも同様の効果が認め
られている。[0004] Similar effects have also been recognized for other omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid.
【0005】アレルギー症状は、体内で抗原抗体反応が
起こり免疫グロブリンE(IgE抗体)が作られ、結果
的に肥満細胞の細胞膜を刺激しヒスタミン、ロイコトリ
エンを放出することによって起こる。放出されたこれら
の物質は、血管透過性を促進させる、平滑筋を収縮させ
るなどの作用があるため、白血球やタンパク質が血管か
ら漏出したり、炎症により気管支を収縮させ喘息を起こ
したりする。[0005] Allergic symptoms occur when an antigen-antibody reaction occurs in the body and immunoglobulin E (IgE antibody) is produced, which eventually stimulates the cell membrane of mast cells and releases histamine and leukotrienes. These released substances have the effect of promoting vascular permeability and contracting smooth muscle, causing white blood cells and proteins to leak from blood vessels, and inflammation that constricts the bronchi, causing asthma.
【0006】このような症状を軽減するために従来より
抗原となる物質を除去したり摂取しないことを基本とし
、抗ヒスタミン剤、副腎皮質ホルモンを経口投与したり
、軟膏として用いたりしている。[0006] Conventionally, in order to alleviate such symptoms, the basic approach has been to remove or avoid ingesting substances that act as antigens, and antihistamines and adrenocortical hormones have been orally administered or used as ointments.
【0007】しかしながら、上記の薬剤による方法は眠
気、胃腸障害、肝臓障害、糖尿病、高血圧などの副作用
をともなううえ、一時的な治療であり、使用しなければ
再び症状がでるなどの問題があった。[0007] However, the above-mentioned drug methods have side effects such as drowsiness, gastrointestinal disorders, liver disorders, diabetes, and high blood pressure, and are only temporary treatments, with problems such as symptoms reappearing if not used. .
【0008】[0008]
【発明が解決しようとする問題点】本発明の目的は、上
記の薬剤による治療の問題点を解決するために、天然の
油脂組成物からなる安全でしかも摂取し易いアレルギー
予防性のある医薬品および食品を提供するものである。[Problems to be Solved by the Invention] The purpose of the present invention is to provide a safe and easy-to-take allergy-preventing drug made of a natural oil and fat composition, in order to solve the above-mentioned problems in treatment with drugs. It provides food.
【0009】[0009]
【課題を解決するための手段】本発明のアレルギー予防
油脂食品はα−リノレン酸含有油脂食品としてエゴマ油
(シソ油)あるいはアマニ油を、またセサミン等のリグ
ナン化合物を含有する油脂としてゴマ油を選択し、これ
らを併用することを特徴とする油脂組成物である。さら
に、甘草エキスあるいは茶抽出物を添加してもよい。[Means for Solving the Problems] The allergy-preventing oil and fat food of the present invention uses perilla oil (perilla oil) or linseed oil as the α-linolenic acid-containing oil and fat food, and sesame oil is selected as the oil and fat containing lignan compounds such as sesamin. This is an oil and fat composition characterized by using these in combination. Additionally, licorice extract or tea extract may be added.
【0010】本発明で用いられるα−リノレン酸はω3
系脂肪酸に属するもので生体内においてリノール酸、ア
ラキドン酸等のω6系脂肪酸と競合している。[0010] The α-linolenic acid used in the present invention is ω3
It belongs to the ω6 fatty acids and competes with ω6 fatty acids such as linoleic acid and arachidonic acid in vivo.
【0011】α−リノレン酸をはじめとするω3系脂肪
酸を摂取することで生体組織中のω6系脂肪酸が減少し
、結果的にアラキドン酸量を減少してロイコトリエンの
産生を抑制することになる。[0011] By ingesting ω3 fatty acids such as α-linolenic acid, ω6 fatty acids in living tissues are reduced, resulting in a decrease in the amount of arachidonic acid and suppression of leukotriene production.
【0012】ω3系脂肪酸のうちエイコサペンタエン酸
は、ロイコトリエンの基質にもなりうるが、ロイコトリ
エンの活性はアラキドン酸由来のものに比べはるかに弱
く、産生量も少ない。[0012] Among the omega-3 fatty acids, eicosapentaenoic acid can also be a substrate for leukotrienes, but the activity of leukotrienes is much weaker than that derived from arachidonic acid, and the amount produced is low.
【0013】以上のようにω3系脂肪酸を摂取すること
によりアラキドン酸からのロイコトリエンの産生が抑制
されることは明確でありアレルギー症状の予防、また治
療に有効であることが確認されている。[0013] As described above, it is clear that the production of leukotrienes from arachidonic acid is suppressed by ingesting omega-3 fatty acids, and it has been confirmed that it is effective in preventing and treating allergic symptoms.
【0014】さらにゴマ油に含有されるセサミン、セサ
ミノール、エピセサミンなど数種のリグナン化合物が△
5不飽和化反応を特異的に抑制することが清水(京都大
)らによって報告された(ハ゛イオサイエンスとインタ
゛ストリ−.,vol.48 No12(1990)
)。Furthermore, several lignan compounds such as sesamin, sesaminol, and episesamin contained in sesame oil
Shimizu (Kyoto University) et al. reported that 5-desaturation reaction was specifically inhibited (Bioscience and Industry., vol. 48 No. 12 (1990)
).
【0015】すなわち、ゴマ油中のセサミン類が炭素数
18の脂肪酸の不飽和化酵素(△9△12、△6)には
まったく影響をあたえず、炭素数20の脂肪酸の△5不
飽和化酵素のみ阻害するためにジホモガンマリノレン酸
からアラキドン酸への産生が抑制される。このことは、
結果的にアレルギー症状の原因になつているロイコトリ
エンの産生を抑えることになる。[0015] That is, the sesamin compounds in sesame oil have no effect on the desaturases of fatty acids with 18 carbon atoms (△9△12, △6), but on the △5 desaturases with fatty acids with 20 carbon atoms. The production of arachidonic acid from dihomogammalinolenic acid is suppressed. This means that
As a result, it suppresses the production of leukotrienes, which are the cause of allergic symptoms.
【0016】ゴマ油に関しては、これまでその特有の芳
香を有すること、酸化安定性が高いことなど知られてお
り、食用油脂や老化防止効果を有する健康食品に利用さ
れてきている。[0016] Sesame oil has been known to have a unique aroma and high oxidation stability, and has been used in edible fats and oils and health foods with anti-aging effects.
【0017】今回の清水らの発見は、天然物からの不飽
和化酵素阻害剤としては初めてであり、またゴマ油の新
しい利用という点からも興味深い。The present discovery by Shimizu et al. is the first desaturase inhibitor made from a natural product, and is also interesting from the point of view of a new use of sesame oil.
【0018】また、茶抽出物および甘草エキスはこれま
で油脂に対する抗酸化性が注目されており、これらを添
加することはα−リノレン酸を多く含む本発明の油脂組
成物の酸化安定性を向上させることになる。一般には上
記油脂はトコフェロール等の抗酸化剤を添加して酸化を
抑えるが、茶抽出物あるいは甘草エキスを添加すること
によりアレルギー予防性はさらに強化される。[0018] Furthermore, tea extract and licorice extract have been attracting attention for their antioxidant properties against fats and oils, and the addition of these will improve the oxidative stability of the fat and oil composition of the present invention containing a large amount of α-linolenic acid. I will let you do it. Generally, antioxidants such as tocopherols are added to the above oils and fats to suppress oxidation, but the allergy preventive properties are further enhanced by adding tea extract or licorice extract.
【0019】本発明者らは、以上のような知見をもとに
異なる特性で、結果的にアレルギーの原因物質であるロ
イコトリエンの産生を抑える2種類の成分を併用するこ
とでより高いアレルギー予防効果があることを見いだし
た。さらに茶抽出物あるいは甘草エキスを添加してもよ
い。[0019] Based on the above findings, the present inventors have discovered that a higher allergy prevention effect can be achieved by combining two types of ingredients that have different properties and, as a result, suppress the production of leukotrienes, which are the causative substances of allergies. I found that there is. Furthermore, tea extract or licorice extract may be added.
【0020】すなわち、本発明者らは、ω3系脂肪酸含
有油脂としてはα−リノレン酸を40〜60%含むエゴ
マ油(シソ油)あるいはアマニ油を、またセサミン類を
含む油脂としてはゴマ油を利用することとし、両者を配
合することによりアレルギー予防効果の高い油脂組成物
を得た。That is, the present inventors used perilla oil (perilla oil) or linseed oil containing 40 to 60% α-linolenic acid as the oil containing ω3 fatty acids, and sesame oil as the oil containing sesamin. By blending the two, an oil and fat composition with a high allergy prevention effect was obtained.
【0021】その配合率としてはエゴマ油90〜50重
量%、ゴマ油10〜50重量%程度の範囲でアレルギー
予防効果に優れた効果が得られる。また、茶抽出物ある
いは甘草エキスを0.1〜2重量%添加してもさらに高
いアレルギー予防効果がえられる。[0021] Excellent allergy prevention effects can be obtained when the blending ratio is in the range of 90 to 50% by weight of perilla oil and 10 to 50% by weight of sesame oil. Moreover, even higher allergy prevention effects can be obtained by adding 0.1 to 2% by weight of tea extract or licorice extract.
【0022】本発明のアレルギー予防油脂食品はエゴマ
油とゴマ油を配合して得られるが、他の成分を配合添加
することは差し支えない。The allergy-preventing oil and fat food of the present invention is obtained by blending perilla oil and sesame oil, but other ingredients may be blended and added.
【0023】特にα−リノレン酸を多く含むために酸化
安定性を維持するためのトコフェロール等の抗酸化剤を
配合してもよい。In particular, since it contains a large amount of α-linolenic acid, an antioxidant such as tocopherol may be added to maintain oxidative stability.
【0024】本発明のアレルギー予防油脂食品はカプセ
ル、錠剤、乳液などとして経口、注射等により投与して
もよく、またサラダ油やマーガリン、ドレッシングなど
に混ぜて食品形態で投与してもよい。The allergy-preventing oil and fat food of the present invention may be administered orally or by injection in the form of capsules, tablets, emulsions, etc., or may be administered in the form of food by mixing it with salad oil, margarine, dressing, etc.
【0025】その投与量は特に規定はないが大人1日あ
たり約2.0〜3.0gで充分な効果が得られる。[0025] Although there are no particular restrictions on the dosage, sufficient effects can be obtained with approximately 2.0 to 3.0 g per day for adults.
【0026】[0026]
【実施例および比較例】本発明を実施例および比較例に
よりさらに詳細に説明する。[Examples and Comparative Examples] The present invention will be explained in more detail with reference to Examples and Comparative Examples.
【0027】[実施例1]花粉症患者 計20名(男
15名、女5名、22〜43歳)を4群にわけて3ヶ月
間にわたって臨床試験をおこない、その結果を表1に示
した。[Example 1] A total of 20 hay fever patients (15 males, 5 females, aged 22 to 43) were divided into 4 groups and a clinical trial was conducted for 3 months. The results are shown in Table 1. Ta.
【表1】[Table 1]
【0028】試験方法については毎年花粉症状が患者に
表れる時期のおよそ1ヶ月ほど前から被験者に毎日10
錠ずつA〜D群の油脂カプセルを経口投与する。[0028] Regarding the test method, each year the subjects were given 10 ml of pollen every day, starting approximately one month before the patient's symptoms of pollen appeared.
The oil capsules of Groups A to D are administered orally in tablets.
【0029】一方、食事をはじめ生活活動には特に制限
はしなかった。On the other hand, there were no particular restrictions on daily activities including meals.
【0030】診断は試験開始日より1ヶ月後、2ヶ月後
、3ヶ月後の計4回実施した。なお判定は、被験者の自
覚症状をもとに、著効、有効、無効、悪化の4段階で評
価した。その結果を表2に示す。[0030] Diagnosis was carried out four times in total, one month, two months, and three months after the test start date. The evaluation was based on the subjects' subjective symptoms in four stages: marked effect, effective, ineffective, and worsening. The results are shown in Table 2.
【表2】[Table 2]
【0031】この結果から、A群のエゴマ油およびB群
のゴマ油の単品使用の場合でも、ある程度効果は認めら
れたが、よりエゴマ油、ゴマ油を併用することにより高
い効果が認められた。[0031] From this result, although some effects were observed even when the perilla oil of group A and sesame oil of group B were used alone, a higher effect was observed when perilla oil and sesame oil were used in combination.
【0032】[実施例2]アトピー性皮膚炎患者24名
(男18名、女6名5〜32歳)を4群にわけて3ヶ月
間にわたって臨床試験をおこなった。4群については実
施例1と同様である。[Example 2] A clinical trial was conducted for 3 months with 24 atopic dermatitis patients (18 males, 6 females, aged 5-32) divided into 4 groups. The fourth group is the same as in Example 1.
【0033】試験中の入浴、食事は特に制限はしなかっ
た。[0033] There were no particular restrictions on bathing or eating during the test.
【0034】診断は実施例1と同様に被験者、および試
験者の意見をもとに4段階評価した。その結果を表3に
示す。[0034] As in Example 1, the diagnosis was evaluated on a four-level scale based on the opinions of the subjects and the examiner. The results are shown in Table 3.
【表3】[Table 3]
【0035】この結果から、やはり実施例1とほぼ一致
する結果が得られた。[0035] From this result, a result almost identical to that of Example 1 was obtained.
【0036】[実施例3]既に花粉症状が表れはじめて
いる30名の男子(23〜48名)をA群、C群、E群
、F群、G群の5群にわけて2ヶ月間にわたり臨床試験
をおこなった。[Example 3] Thirty boys (23 to 48) who had already begun to show pollen symptoms were divided into 5 groups: A, C, E, F, and G for 2 months. A clinical trial was conducted.
【0037】試験方法については、花粉症状が表れ始め
た被験者から順次、試験を開始した。投与方法、診断は
実施例1および2と同様におこなった。この結果を表4
に示す。[0037] Regarding the test method, the test was started sequentially from the subjects who started to show pollen symptoms. The administration method and diagnosis were performed in the same manner as in Examples 1 and 2. This result is shown in Table 4.
Shown below.
【表4】[Table 4]
【0038】この結果から、エゴマ油とゴマ油の配合比
率においてゴマ油を50%〜10%程度の間で抗アレル
ギー効果は充分あるといえる。しかし、ゴマ油を50%
以上配合するとアレルギー予防効果は低下する。[0038] From this result, it can be said that a sufficient anti-allergy effect is achieved when the blending ratio of perilla oil and sesame oil is between about 50% and 10%. However, 50% sesame oil
If more than 100% is added, the allergy prevention effect will be reduced.
【0039】[実施例4]アトピー性皮膚炎患者12名
(3〜14歳)をC群、H群、I群にわけて、3カ月間
にわたり臨床試験をおこなった。[Example 4] Twelve patients (3 to 14 years old) with atopic dermatitis were divided into Groups C, H, and I, and a clinical trial was conducted for 3 months.
【0040】試験方法については実施例1〜3と同様で
ある。結果を表5に示す。The test method was the same as in Examples 1-3. The results are shown in Table 5.
【表5】[Table 5]
【0041】この結果から、茶抽出液および甘草エキス
を添加することにより、アレルギー予防効果はやや強め
られる傾向があった。[0041] From these results, it was found that the allergy preventive effect tended to be somewhat strengthened by adding tea extract and licorice extract.
【0042】[0042]
【発明の効果】現在、成人では花粉症が、また小児では
アトピー性皮膚炎が増加しているにもかかわらず、それ
らの予防法、治療法は確立されてはいない。[Effects of the Invention] Currently, although hay fever is increasing in adults and atopic dermatitis is increasing in children, no methods for preventing or treating these diseases have been established.
【0043】本発明は、これまでの薬剤にたよる治療法
とは異なり、通常の食生活のなかで不足しているα−リ
ノレン酸をエゴマ油で補い、なおかつα−リノレン酸と
相乗効果をもつセサミン類をゴマ油からとることを目的
とした、医薬品および食品として安全なアレルギー予防
油脂組成物である。[0043] Unlike conventional treatment methods that rely on drugs, the present invention supplements α-linolenic acid, which is deficient in the normal diet, with perilla oil, and also has a synergistic effect with α-linolenic acid. This is an allergy-preventing oil and fat composition that is safe for use in medicine and food, and aims to extract sesamin from sesame oil.
Claims (3)
ミン等のリグナン化合物を有成分として含有することを
特徴とするアレルギー予防薬および食品。1. Allergy preventive medicine and food, characterized by containing oil and fat having α-linolenic acid as a main component and a lignan compound such as sesamin as active ingredients.
油)もしくはアマニ油であり、セサミン等の有効成分が
ゴマ油より得られる特許請求の範囲第1項記載のアレル
ギー予防薬および食品。2. The allergy preventive medicine and food according to claim 1, wherein the α-linolenic acid-containing fat or oil is perilla oil (perilla oil) or linseed oil, and the active ingredient such as sesamin is obtained from sesame oil.
分を含有する油脂組成物に茶抽出物または甘草エキスを
添加して得られる特許請求の範囲第1項記載のアレルギ
ー予防薬および食品。3. The allergy preventive drug and food according to claim 1, which are obtained by adding a tea extract or a licorice extract to an oil and fat composition containing active ingredients such as α-linolenic acid and sesamin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3075882A JPH04290822A (en) | 1991-03-15 | 1991-03-15 | Allergy preventing medicine and food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3075882A JPH04290822A (en) | 1991-03-15 | 1991-03-15 | Allergy preventing medicine and food |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04290822A true JPH04290822A (en) | 1992-10-15 |
Family
ID=13589104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3075882A Pending JPH04290822A (en) | 1991-03-15 | 1991-03-15 | Allergy preventing medicine and food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04290822A (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04368326A (en) * | 1991-06-15 | 1992-12-21 | Suntory Ltd | New composition |
JPH06227977A (en) * | 1993-02-01 | 1994-08-16 | Suntory Ltd | Active oxygen eliminating agent |
EP0681788A2 (en) * | 1994-05-12 | 1995-11-15 | Suntory Limited | Dioxabicyclo[3.3.0] octane derivatives, e.g. sesamin etc., for prevention or alleviation of allergy symptoms |
JPH08116878A (en) * | 1994-10-26 | 1996-05-14 | Nippon Oil & Fats Co Ltd | Alpha-linolenic acid-containing oil-and-fat composition and its use |
JPH09121766A (en) * | 1995-10-31 | 1997-05-13 | Meiji Milk Prod Co Ltd | Food for infant having regulated n-6 series/n-3 series fatty acid ratio |
JP2001218558A (en) * | 2000-02-10 | 2001-08-14 | Fuji Oil Co Ltd | Oil-and-fat composition |
JP2002051746A (en) * | 2000-08-02 | 2002-02-19 | Dae Chang Food Co Ltd | Method for producing toasted laver with seasoning material, and toasted laver |
JP2004035456A (en) * | 2002-07-03 | 2004-02-05 | Pola Chem Ind Inc | Promoter for keratinocyte maturation and oral administration composition containing the same |
WO2006106926A1 (en) * | 2005-03-31 | 2006-10-12 | Suntory Limited | Lignane compound-containing oil-in-water emulsion and composition comprising the same |
US7384656B2 (en) | 2004-02-05 | 2008-06-10 | Access Business Group International Llc | Anti-allergy composition and related method |
CN109475589A (en) * | 2016-06-28 | 2019-03-15 | 风之星医疗有限公司 | Extractive of perilla composition |
JP2019167324A (en) * | 2018-03-26 | 2019-10-03 | 森 昭夫 | Method for suppressing allergy symptoms |
JP2020145941A (en) * | 2019-03-12 | 2020-09-17 | 日本製粉株式会社 | Allergic rhinitis inhibitory composition |
-
1991
- 1991-03-15 JP JP3075882A patent/JPH04290822A/en active Pending
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04368326A (en) * | 1991-06-15 | 1992-12-21 | Suntory Ltd | New composition |
JPH06227977A (en) * | 1993-02-01 | 1994-08-16 | Suntory Ltd | Active oxygen eliminating agent |
EP0681788A2 (en) * | 1994-05-12 | 1995-11-15 | Suntory Limited | Dioxabicyclo[3.3.0] octane derivatives, e.g. sesamin etc., for prevention or alleviation of allergy symptoms |
JPH0826989A (en) * | 1994-05-12 | 1996-01-30 | Suntory Ltd | Preventing or improving agent for allergic symptom |
EP0681788A3 (en) * | 1994-05-12 | 1998-01-14 | Suntory Limited | Dioxabicyclo[3.3.0] octane derivatives, e.g. sesamin etc., for prevention or alleviation of allergy symptoms |
JPH08116878A (en) * | 1994-10-26 | 1996-05-14 | Nippon Oil & Fats Co Ltd | Alpha-linolenic acid-containing oil-and-fat composition and its use |
JPH09121766A (en) * | 1995-10-31 | 1997-05-13 | Meiji Milk Prod Co Ltd | Food for infant having regulated n-6 series/n-3 series fatty acid ratio |
JP2001218558A (en) * | 2000-02-10 | 2001-08-14 | Fuji Oil Co Ltd | Oil-and-fat composition |
JP2002051746A (en) * | 2000-08-02 | 2002-02-19 | Dae Chang Food Co Ltd | Method for producing toasted laver with seasoning material, and toasted laver |
JP2004035456A (en) * | 2002-07-03 | 2004-02-05 | Pola Chem Ind Inc | Promoter for keratinocyte maturation and oral administration composition containing the same |
US7384654B2 (en) | 2004-02-05 | 2008-06-10 | Access Business Group International Llc | Anti-Allergy composition and related method |
US7384656B2 (en) | 2004-02-05 | 2008-06-10 | Access Business Group International Llc | Anti-allergy composition and related method |
WO2006106926A1 (en) * | 2005-03-31 | 2006-10-12 | Suntory Limited | Lignane compound-containing oil-in-water emulsion and composition comprising the same |
JPWO2006106926A1 (en) * | 2005-03-31 | 2008-09-11 | サントリー株式会社 | Oil-in-water emulsion containing lignan compounds and composition containing the same |
JP5096138B2 (en) * | 2005-03-31 | 2012-12-12 | サントリーホールディングス株式会社 | Oil-in-water emulsion containing lignan compounds and composition containing the same |
US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
CN109475589A (en) * | 2016-06-28 | 2019-03-15 | 风之星医疗有限公司 | Extractive of perilla composition |
US20190151390A1 (en) * | 2016-06-28 | 2019-05-23 | Inqpharm Group Sdn Bhd | Perilla extract composition |
EP3474874B1 (en) * | 2016-06-28 | 2023-12-13 | WindStar Medical GmbH | Perilla extract composition |
JP2019167324A (en) * | 2018-03-26 | 2019-10-03 | 森 昭夫 | Method for suppressing allergy symptoms |
JP2020145941A (en) * | 2019-03-12 | 2020-09-17 | 日本製粉株式会社 | Allergic rhinitis inhibitory composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10342773B2 (en) | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient | |
JP5784674B2 (en) | Self-emulsifying composition of ω3 fatty acid | |
JPH0232017A (en) | Essential fatty acid composition and it production | |
JPH02243623A (en) | Therapy by fatty acid and aomposition thereof | |
CA2449898A1 (en) | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport | |
JPH04290822A (en) | Allergy preventing medicine and food | |
KR20000035924A (en) | Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia | |
US20070020340A1 (en) | Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension | |
JPH0558902A (en) | Fat and oil composition for preventing allergy | |
EP0391218B1 (en) | Agent for the atopy prophylaxis | |
JPH09291299A (en) | Antiallergic oil and fat composition and use | |
JPH09278662A (en) | Antiallergic agent | |
JP2002302441A (en) | Composition and food and drink for obtunding symptom of premenstrual syndrome | |
JP2006306813A (en) | Mast cell increase inhibitor | |
CN106031722A (en) | Composition for treating diseases caused by body and nervous system disorder or inflammation, and applications thereof | |
WO2005070435A1 (en) | Agent for improving dynamic eyesight | |
AU2021249347A1 (en) | Composition for improving friendliness and/or empathetic capacity | |
JPH0662795A (en) | Antiallergic food | |
JP2002360220A (en) | Health supplement food having improving action for interruption in circulation of blood | |
JPH04169525A (en) | Composition having serum lipid-improving function | |
US20030086981A1 (en) | Glycerin fatty acid ester for palliate a symptom of premenstrual syndrome, a palliative of premenstrual syndrome, oil or fat composition for palliate a symptom of premenstrual syndrome, and food and drink for palliate a symptom of premenstrual syndrome | |
EP2049098A2 (en) | Omega-3 fatty acids for use in treating resistant hypertension | |
JPH09187248A (en) | Antiallergic food | |
JP3816545B2 (en) | Composition for treatment of cutaneous pruritus and composition for treatment of hyperparathyroidism in an artificial dialysis patient | |
JP2020503388A (en) | Omega-3 fatty acid composition for preventing and / or treating cachexia |